Korean Stroke Cohort for functioning and rehabilitation (KOSCO)-II is a large, multi-centre prospective cohort study for all acute first-ever stroke patients admitted to participating hospitals in nine distinct areas of Korea. This study is designed as a 10-year, longitudinal follow-up investigating the residual disabilities, activity limitations, and quality of life issues arising in patients suffering from first-ever stroke as previous similar stroke cohort with KOSCO. The main objectives of this study are to identify and compare the factors that influence residual disability and long-term quality of life in first-ever acute stroke patients with KOSCO. The secondary objectives of this study are to determine and compare the risk of mortality and recurrent vascular events in first-ever acute stroke patients with KOSCO. Investigators will investigate longitudinal health behaviors and patterns of healthcare utilization, including stroke rehabilitation care. Investigators will also investigate the long-term health status, mood, and quality of life in stroke patient caregivers. In addition, investigators will identify baseline and ongoing characteristics that are associated with secondary outcomes.

开始日期2020-01-01

申办/合作机构

Samsung Medical Center

NL-OMON46715

/ Completed临床3期IIT

Distal pancreatectomy, minimally invasive or open, for malignancy (DIPLOMA) - DIPLOMA-trial

开始日期2018-05-03

申办/合作机构-

100 项与西他生坦钠相关的临床结果

登录后查看更多信息

100 项与西他生坦钠相关的转化医学

登录后查看更多信息

100 项与西他生坦钠相关的专利（医药）

登录后查看更多信息

294

项与西他生坦钠相关的文献（医药）

2025-10-01·JOURNAL OF INTERNATIONAL MEDICAL RESEARCH

Cardiopulmonary bypass–mediated lung ischemia–reperfusion injury: A protective role of sitaxentan

Article

作者: Chen, Yirong ; Wang, Zhengjia ; Mo, Liqun ; Liu, Li ; Bai, Yiping ; Zhan, Renshu ; Zhang, Yingying

Background:

Cardiopulmonary bypass is widely used in cardiac surgery but often leads to lung ischemia–reperfusion injury, a major cause of morbidity and mortality. Despite advances in critical care, effective prevention remains challenging. Sitaxentan, a selective endothelin receptor antagonist, has shown protective effects in ischemia–reperfusion models, suggesting its potential in mitigating lung ischemia–reperfusion injury. This study investigated the efficacy of sitaxentan in reducing lung ischemia–reperfusion injury during cardiopulmonary bypass.

Methods:

Twenty-four female beagles were divided into sham, cardiopulmonary bypass, and endothelin receptor antagonist (sitaxentan-treated) groups. Hemodynamics, arterial blood gas, lung damage scores, wet/dry ratio, and levels of various biomarkers were evaluated.

Results:

Lung damage scores in the endothelin receptor antagonist group were lower than those in the cardiopulmonary bypass group but higher than those in the sham group ( P < 0.05). The wet/dry ratio was lowest in the sham group and higher in the cardiopulmonary bypass group than that in the endothelin receptor antagonist group ( P < 0.05). Caspase-3 and hypoxia inducible factor-1α levels were intermediate in the endothelin receptor antagonist group compared with those in the cardiopulmonary bypass and sham groups ( P < 0.05). In contrast, phosphorylated-endothelial nitric oxide synthase, phosphorylated protein kinase B, tumor necrosis factor-α, and interleukin-6 levels were higher in the endothelin receptor antagonist group than in the cardiopulmonary bypass and sham groups ( P < 0.05). Malondialdehyde level was higher and superoxide dismutase level was lower in the cardiopulmonary bypass and endothelin receptor antagonist groups than in the sham group ( P < 0.05).

Conclusions:

Sitaxentan may offer a novel therapeutic approach to attenuate lung ischemia–reperfusion injury in clinical settings by regulating the hypoxia inducible factor-1α/phosphorylated protein kinase B/phosphorylated-endothelial nitric oxide synthase pathway.

2024-11-01·Journal of Computational Biophysics and Chemistry

Molecular Docking, Quantum Mechanics and Molecular Dynamics Simulation of Anti-CAD Drugs Against High-Risk Xanthine Dehydrogenase Variants Associated with Oxidative Stress Pathways

作者: Sudhan, M. ; Ahmed, Shiek S. S. J. ; Emran, Talha Bin ; Attia, Sabry M. ; Ahmad, Sheikh F. ; Janakiraman, V.

Xanthine dehydrogenase (XDH) contributes significantly to generating reactive oxygen species in coronary artery disease (CAD). XDH has been proposed as a therapeutic target, but its genetic variants could affect protein structure and drug response. We aimed to assess protein structure modification occur due to genetic variants and to screen 215 CAD drugs for their utility in personalized CAD treatment against the XDH variants. A series of computational methods were implemented to identify pathogenic variants that cause XDH structure instability localized at the con served regions contributing to functional significance. Then, the XDH structures with the pathogenic variants were modeled using two different approaches to select the best models for docking with the CAD drugs. Finally, the stability of the docked complexes and their ability to transfer electrons were evaluated using molecular dynamics (MD) simulations and quantum mechanics/molecular mechanics (QM/MM) calculation. Among 751 variants examined; R149C and Q919R showed high pathogenicity, localized in conserved regions could alter protein structure and function. Further, docking of CAD drugs against XDH (native, R149C and Q919R) showed vericiguat with higher affinity, ranging from −7.95 kcal/mol to −10.41 kcal/mol, than the well-known XDH inhibitor (febuxostat, −5.73 kcal/mol to −8.35 kcal/mol). This indicates that vericiguat will be effective in CAD treatment, regardless of the XDH variants. Additionally, MD simulation and QM/MM confirmed vericiguat stability and electron transfer ability to form hydrogen bonds with the XDH protein. In conclusion, vericiguat will be beneficial for the personalized treatment of CAD by inhibiting XDH variants. Additional clinical studies are necessary to confirm our findings.

2024-10-01·ESC Heart Failure

Pulmonary artery denervation versus conventional therapies for PAH: a systematic review and updated network meta‐analysis

Review

作者: Wei, Yongyue ; Chen, Feng ; Chen, Shao‐liang ; Pan, Zoucheng ; Kan, Jing ; Zhang, Longyao ; Wang, Xiang ; Wu, Xiaoyu

Abstract:

Aims:

A recent guideline presented by the ESC Congress in 2022 had indicated a novel therapy targeted at pulmonary artery hypertension, known as pulmonary artery denervation (PADN), which get inspired from a laboratorial trial that could lowering the pulmonary artery pressure through the intervention on the animals. Our aim is to conduct a network meta‐analysis to compare the efficacy and safety of PADN from six aspects with the current conventional therapies.

Methods and results:

According to the PRISMA guidance, databases including Ovid, ClinicalTrials.gov, Medline, Embase, and PubMed were searched from inception to 22 August 2023, along with a full assessment of the previous five meta‐analyses. Data were extracted and curated for Bayesian network meta‐analysis. The primary outcome was the change in the 6‐min walking distance (6MWD) from baseline with a secondary outcome called change in mean pulmonary artery pressure (mPAP) from baseline. The four safety outcomes included risk of clinical worsening, hospitalization, mortality and severe adverse events (SAEs). The comparison is structured on a contrast model based on 65 randomized controlled trials (RCTs) on PADN and the other conventional mainstream drugs. PADN had a better effect in improving 6MWD than Placebo (−77.76 m, 95% CI: −102.04 to −54.34 m), Macitentan (−65.32 m, 95% CI: −95.34 to −36.1 m), Bosentan (−64.5 m, 95% CI: −94.7 to −35.07 m), Iloprost (−62.66 m, 95% CI: −99.48 to −27.13 m), Oxygen (−62.42 m, 95% CI: −100.01 to −25.78 m), Treprostinil (−62.01 m, 95% CI: −89.04 to −35.61 m), Riociguat (−60.59 m, 95% CI: −86.11 to −35.98 m), Selexipag (−47.2 m, 95% CI: −85.61 to −10.19 m), Sildenafil (−44.92 m, 95% CI: −74.43 to −16.15 m), or Sitaxsentan (−39.53 m, 95% CI: −78.99 to −0.76 m). PADN had a better antihypertensive effect than placebo and showed statistical significant lower risks to induce clinical worsening and re‐hospitalization than treprostinil, riociguat, and placebo groups. No statistically significant difference in risk of mortality and severe adverse events was observed between PADN versus the other interventions.

Conclusions:

Compared with 16 types of conventional therapies and Placebo, PADN has advantage over nine single therapies and Placebo in improving 6MWD and appears to be better than two types of dual‐drug combined therapies while with no statistical significance. PADN shows a favourable antihypertensive effect on mPAP and has a lower risk to trigger clinical worsening or hospitalization, while its risk on mortality and severe adverse events is still inconclusive.

项与西他生坦钠相关的新闻（医药）

2024-08-22

·Pharmaceutical Technology

Leo Pharma’s Timber bet falls flat following Phase III failure

There is currently no treatment approved for ichthyosis by the FDA. Image credit: Shutterstock / JHVEPhoto. A year after hedging its bets on Timber Pharmaceuticals’ dermatology pipeline, Leo Pharma has reported a Phase III failure for the lead asset it acquired at the time. TMB-001, a topical ointment formulation of isotretinoin, came up short in the late-stage trial for patients with moderate to severe congenital ichthyosis. Ichthyosis is an umbrella term for congenital skin conditions that cause dry and scaly skin. In the Phase III ASCEND trial (NCT05295732), Leo stated the therapy did not demonstrate a statistically significant improvement in patients compared to those treated with a vehicle. This meant the primary and key secondary endpoints were not met. The results do not support US regulatory submission, the Danish privately owned company stated in a 21 August press release. There is currently no treatment approved for ichthyosis by the US Food and Drug Administration (FDA). Instead, the condition is managed by hydrating the skin with creams and lotions. See Also: A comprehensive guide to supply chain management for specialty drugs Codiak BioSciences gets grant for extracellular vesicles for disease treatment and prevention The ASCEND trial had a three-week induction, a nine-week treatment period, and – for eligible patients – a 12-week open-label maintenance regimen. A total of 209 patients aged six years and over were enrolled in the study. Timber’s CEO John Koconis said: “We are disappointed and saddened by the results of the Phase III trial. After encouraging phase 2b results, we observed an unexpectedly high vehicle response in this trial.” A previous Phase IIb trial evaluating the ointment achieved its primary endpoint of a 50% reduction in the Visual Index for Ichthyosis Severity scale score versus baseline. Leo Pharma spent $36m to acquire a bankrupt Timber in August 2023, including a $14m upfront payment. At the time, Timber had received orphan, fast-track, and breakthrough designations from the FDA. Following the acquisition, the company became a fully owned subsidiary of Leo Pharma. Leo Pharma’s chief development officer Kreesten Meldgaard Madsen said the company remains committed to dermatologic diseases but added “as is the case for all pharmaceutical research, not all trials are successful”. Leo Pharma stated the trial results will not impact its 2024 financial results. The company had a regulatory win elsewhere in the dermatology space in June this year, when its single-dose autoinjector for atopic dermatitis Adbry (tralokinumab-ldrm) received FDA approval . Whilst the clinical journey of TMB-001 stutters, Timber also has TMB-003 (sitaxentan) – a topical ET-A receptor antagonist in preclinical testing for sclerotic skin diseases.

临床2期临床3期临床结果快速通道突破性疗法

2024-05-14

·药融圈

值得关注的治疗领域：皮肤制药公司被并购

▲5月30-31日第八届广州生物医药创新者峰会扫码立即报名注：本文不构成任何投资意见和建议，以官方/公司公告为准；本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及），不代表平台立场。任何文章转载需得到授权。丹麦制药巨头利奥制药（LEO）是一家引领标准治疗，惠及皮肤疾病患者及其家庭和社会的全球公司。值得留意的是利奥制药的创始人August Kongsted是诺和诺德之Nordisk的天使投资人。LEO是一家超百年的企业；成立于1908年，隶属于利奥基金会，数十年来一直致力于研发，以推动皮肤病科学的发展。如今，利奥制药为不同严重程度的疾病提供了广泛的治疗方案。利奥制药总部位于丹麦，拥有全球员工4600人，为全球数千万患者提供服务。2022年利奥制药的净销售收入为106亿丹麦克朗（约合110亿元人民币）。药融云数据www.pharnexcloud.com监测显示：2024年1月，利奥制药完成对Timber Pharmaceuticals（纽约证券交易所股票代码：TMBR）的战略资产TMB-001及其他资产的收购。（要知道停牌收购前市值仅117万美元）药融圈获悉：该交易的总交易价值3600万美元（约合2.605亿人民币），其中（i）初始预付对价为1400万美元，（ii）在实现特定里程碑后，可额外支付至多2200万美元的或有价值权（CVR）。TMB-001项目旨在开发一种外用药物治疗方法，用于治疗多种中度至重度亚型先天性鱼鳞病（Congenital Ichthyosis ,CI）--一种罕见的皮肤病，存在大量未被满足的需求，且尚无正规获批的处方疗法（off-label 此前居多）。TMB-001项目按原计划继续进行。Timber Pharmaceuticals的所有员工将迁移至利奥制药位于美国新泽西州的办公室。 Timber专注于开发罕见皮肤病的非全身性治疗方法，包括先天性鱼鳞病（CI）和硬化性皮肤病（sclerotic skin diseases）。药融云数据www.pharnexcloud.com；词条TMB-001是一种活性药物成分（API）为异维甲酸/异维A酸的研究性外用制剂（改良新药）（关联阅读：505b2是否会是诗和远方？），目前美国只有异维甲酸的口服制剂。该新制剂已获得FDA的孤儿药项目资质；快速通道和突破性疗法的认证。TMB-001在II期临床研究已显示出积极的结果，III期临床研究的招募工作目前正在美国和欧洲进行。Timber Pharmaceuticals另一款候选药物Sitaxsentan 是选择性内皮素A (ETA) 受体拮抗剂，适应症为硬化性皮肤病。此前Christophe Bourdon/利奥制药CEO表示：“我们很高兴在2024年将TMB-001加入我们的产品线，并欢迎Timber Pharmaceuticals的员工加入利奥制药。这项交易将进一步加强我们的产品管线，使我们拥有一项具有战略意义的Ⅲ期资产，并可能有助于目前患有尚无合适治疗方案的衰竭性疾病患者的治疗。”参考：NMPA/CDE；药融云数据www.pharnexcloud.com；FDA/EMA/PMDA；相关公司公开披露；利奥制药（LEO）；www.timberpharma.com；https://www.timberpharma.com/tmb-003-topical-subcutaneous-et-a-r；等等。本文仅用于向医疗卫生专业人士提供科学信息，不代表平台立场，不作任何用药推荐5月 • 第八届大湾区生物医药创新者峰会

并购孤儿药突破性疗法临床3期临床2期

2024-04-10

·赛柏蓝

全新机制高血压用药上市，院内降压药排名大洗牌？

编者按：本文来自医药地理，作者南波万；赛柏蓝授权转载，编辑凯西2024年3月20日，Idorsia 宣布FDA已批准TRYVIO™（Aprocitentan）与其他抗高血压药物联合用于治疗其他药物未得到充分控制的成年患者的高血压（难治性高血压）。TRYVIO（Aprocitentan）是一款新型口服双重内皮素A/B受体（ETA/ETB）拮抗剂，可有效抑制内皮素ET-1与ETA和ETB的结合。在TRYVIO获得批准之前，没有针对ET通路的全身性抗高血压药物，Tryvio®是近40年来获得批准的通过新的治疗途径起作用的首款口服抗高血压治疗剂。01获批的临床试验FDA此次批准是依据一项临床Ⅲ期研究PRECISION（NCT03541174）的试验结果。该研究是一项多中心、盲法、随机临床试验，评估了Approcitentan在收缩压≥140 mmHg且至少服用三种降压药的成年人中的疗效。图：PRECISION III期临床试验来源：Pharma ONE智能药物大数据分析平台，中国医药工业信息中心结果显示，该研究达到了主要终点，即Aprocitentan组患者的坐位收缩压（SiSBP）降低幅度显著大于安慰剂组。即接受Aprocitentan治疗的患者4周后SiSBP得到显著降低，与安慰剂组相比，12.5mg组和25mg组的差异分别为-3.8mmHg（p=0.0042）和-3.7mmHg（p=0.0046）。此外，该研究也达到了关键次要终点，在第36~40周期间，接受Aprocitentan治疗的患者的SiSBP较安慰剂组持续降低，差异为-5.8mmHg（p<0.0001），维持时间长达48周。02作用机制内皮素（ET）是一种强效肽类血管收缩剂，其收缩血管的能力比去甲肾上腺素强100倍。ET是由21个氨基酸组成的活性多肽，有ET-1、ET-2和ET-3三种亚型，其受体分为ETA和ETB。ET-1是ET肽家族中最主要的成员，主要在血管内皮细胞和培养的平滑肌细胞中合成，其与高血压发病机制密切相关，可引起交感神经激活、醛固酮合成和分泌增加、内皮功能障碍、血管肥大和重塑以及纤维化。Aprocitentan是一款靶向双重ETA/ETB受体拮抗剂，通过阻断ET-1与血管平滑肌细胞上的ETA和ETB受体的结合，抑制血管收缩，起到降低血压的作用。图：Aprocitentan的作用机制03内皮素拮抗剂市场情况顽固性高血压是指在改善生活方式的基础上，完全依从降压药物（至少3种）治疗后，血压水平仍高于目标水平的心血管疾病。内皮素（ET）途径在顽固性高血压的发展中起关键性作用。除了高血压，大量研究表明内皮素在冠心病、肺动脉高压、心衰、脑梗死、动脉粥样硬化、多发性硬化、肾病综合征、类风湿性关节炎、糖尿病等多种疾病的发生发展过程中有着较为重要的病理生理意义。不仅如此，内皮素受体还具有与细胞增殖和凋亡等基本细胞过程相关的多种功能，因此，内皮素受体也成为癌症治疗的关键靶点。ET受体拮抗剂可能有益于多种疾病的治疗，具有重要的临床治疗价值。截至目前，FDA共批准了6款ETA/ ETB拮抗剂，其中大部分药品获批的适应症为肺动脉高压，包括2001年获批上市用于治疗肺动脉高压的首创药物ETA+ ETB双重拮抗剂Bosentan（波生坦）；2006年曾获批上市的Sitaxentan（西他生坦），由于在报告中观察到暴发性肝毒性后已被撤市；2007年获批用于治疗肺动脉高压的ETA受体选择性拮抗剂Ambrisentan (安立生坦)；2013年获批同样用于治疗肺动脉高压的ETA+ETB双重拮抗剂Macitentan（马昔腾坦），Aprocitentan是Macitentan的活性代谢产物，具有更长的半衰期（48h vs. 14h）；2023年获批用于治疗IgA肾病的ETA+AT1R双重拮抗剂Sparsentan（斯巴生坦）。而此次Aprocitentan（阿普昔腾坦）是FDA批准的第六款内皮素受体拮抗剂，也是其中第一款适应症为治疗高血压的药物。042023样本医院降压药排名目前市场上常见的降压药按照其作用机制分为ACE抑制剂（血管紧张素转换酶抑制剂）、ARBs（血管紧张素Ⅱ受体拮抗剂）、钙通道阻滞剂、利尿剂、β受体阻滞剂以及中枢性α受体激动剂等。2023年全国样本医院用药市场（包含全国24个省/市/自治区近700家二三级医院药品采购数据）中高血压化药销售额约为64.53亿元。样本医院排名前10的药品（按通用名计）中，表现最为亮眼的无疑是诺华的沙库巴曲缬沙坦钠片（商品名：诺欣妥），不仅一举超过硝苯地平和美托洛尔，以7.89亿元的销售额位居榜首，而且其增速同样十分迅猛，较去年同比增长约51%。沙库巴曲缬沙坦钠片是全球首个血管紧张素受体脑啡肽酶抑制剂（ARNI），于2015年7月获FDA批准上市用于治疗心衰，2017年获NMPA批准进入国内市场，2019年起进入国家医保乙类谈判目录，2021年在中国率先获批用于原发性高血压治疗。诺华在中国市场为诺欣妥分别申报了组合物专利（专利号：ZL201110029600.7）和晶型专利（专利号：ZL200680001733.0/ZL201210191052.2），尤其是独特的晶型专利让诺欣妥在中国市场的独占期可持续到2026年11月。2023年8月，南京方生和医药的一心坦采用了3个结晶水的新晶型，规避了原研含有2.5个结晶水的晶型专利障碍，从而实现了仿制药的合法提前上市，成为沙库巴曲缬沙坦钠片的首仿药。表：诺欣妥在中国专利布局相比之下，去年销售冠军硝苯地平的表现就有些不理想，销售额下滑明显，同比下降约66%，排名跌落至第六名。同样，美托洛尔销售额也下滑明显（-42%），从第二名跌至第三名。表：2023样本医院治疗高血压化药销售额TOP 10来源：PDB药物综合数据库，中国医药工业信息中心05小结与展望Aprocitentan以全新的机制进入高血压药赛道，其降压效果究竟如何还有待市场的进一步检验。除此之外，近年来，长效高血压药的概念也十分火热，Zilebesiran作为一种皮下给药、一针管半年、靶向血管紧张素原（AGT）的在研RNAi治疗药物，一直备受关注。日前正在进行的2024年美国心脏病学会（ACC）年会上，Alnylam公司公布了与罗氏联合开发的zilebesiran在治疗高血压患者的II期临床试验KARDIA-2中获得的积极结果。结果显示，表明对于高血压控制不佳患者，zilebesiran与标准降压药联用，可带来额外的降压获益，降压效果可维持6个月。图：KARDIA-2试验设计来源：Alnylam官网根据《中国高血压临床实践指南》，中国成人高血压人数约2.45亿，且越来越年轻化和普遍化，血压的防控至关重要。期待这些新机制的降压药物能尽早进入中国市场，惠及更多中国患者。END内容沟通：13810174402医药代表交流群扫描下方二维码加入银发经济市场机遇交流群扫描下方二维码加入左下角「关注账号」，右下角「在看」，防止失联

临床结果临床3期临床成功

100 项与西他生坦钠相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D08517	西他生坦钠	C02KX03	DB06268

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
肺性高血压	欧盟	Pfizer Ltd.	2006-08-10
肺性高血压	冰岛	Pfizer Ltd.	2006-08-10
肺性高血压	列支敦士登	Pfizer Ltd.	2006-08-10
肺性高血压	挪威	Pfizer Ltd.	2006-08-10
肺动脉高压	欧盟	Pfizer Ltd.	2006-08-10
肺动脉高压	冰岛	Pfizer Ltd.	2006-08-10
肺动脉高压	列支敦士登	Pfizer Ltd.	2006-08-10
肺动脉高压	挪威	Pfizer Ltd.	2006-08-10

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
特发性肺动脉高压	临床3期	美国	Encysive Pharmaceuticals, Inc.	2003-05-01
慢性肾病	临床2期	英国	Pfizer Inc.	2007-05-09
蛋白尿	临床2期	英国	Pfizer Inc.	2007-05-09
僵硬	临床2期	英国	Pfizer Inc.	2007-05-09
心脏病	临床2期	美国	Pfizer Inc.	2006-08-10
舒张期心力衰竭	临床2期	美国	Pfizer Inc.	2006-03-27
舒张期心力衰竭	临床2期	加拿大	Pfizer Inc.	2006-03-27
系统性硬皮病	临床前	美国	Timber Pharmaceuticals LLC	2022-01-30
硬化症	临床前	美国	Timber Pharmaceuticals LLC	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT00810732 (FCRD01, CTgov)	临床2期	蛋白尿 \| 僵硬 \| 慢性肾病	27	Open (Sitaxsentan)	製簾鹹積壓構齋蓋範餘(鑰壓鬱製膚壓壓壓網繭) = 願蓋憲顧齋蓋壓鑰窪遞鬱鹹顧襯網襯獵鹹鏇觸 (憲壓廠構鑰艱獵蓋顧築, 1.77) 更多	-	2023-07-06
				Placebo (Placebo)	製簾鹹積壓構齋蓋範餘(鑰壓鬱製膚壓壓壓網繭) = 繭願膚鑰構壓窪願糧餘鬱鹹顧襯網襯獵鹹鏇觸 (憲壓廠構鑰艱獵蓋顧築, 1.96) 更多
NCT00303498 (CTgov)	临床2期	舒张期心力衰竭	200	Placebo	鑰廠築觸襯鏇選鹽膚醖(淵鬱醖廠鑰壓糧艱壓鹽) = 醖構積廠築鑰蓋鹹網衊齋範壓壓齋築廠壓製觸 (構鹽鹹鑰衊觸簾衊齋鏇, 顧積鑰廠醖築憲衊糧簾 ~ 醖願鬱願衊襯蓋範衊窪) 更多	-	2023-01-04
NCT00838383 (FCAD02, CTgov)	临床2期	心脏病	29	Placebo	鹽餘鏇窪鏇餘窪淵鬱鑰(糧繭鏇繭製選淵願鑰膚) = 壓顧夢糧憲蓋積夢廠構憲夢選構鏇齋齋淵選觸 (膚齋積範願範艱艱構選, 260.172) 更多	-	2022-09-08
NCT00744211 (CTgov)	N/A	心脏病	29	Vehicle (Vehicle)	繭鏇鹹齋網製廠築鹽糧(鹽鑰鬱齋顧鏇鏇夢醖鑰) = 網淵餘鏇範餘鹽積廠憲鑰憲鬱窪廠窪繭鹹襯鏇 (鹹顧膚淵夢遞製糧選鬱, 19.9) 更多	-	2017-11-09
				1mg/kg sitaxsentan sodium (ET-ARA 1mg/kg)	製廠夢築製鑰觸艱壓淵(繭夢糧簾構獵積蓋膚夢) = 窪製壓憲獵鑰觸衊繭憲鬱醖鬱齋觸鹽觸壓襯製 (遞顧糧艱獵簾鬱衊積遞, 觸壓衊鏇鹹鑰艱蓋鏇鹽 ~ 壓膚鹽淵襯鹹積網觸遞) 更多
NCT00810732 (Pubmed \| J Am Heart Assoc)	临床2期	慢性肾病	27	Sitaxentan	淵鏇製膚鑰鹽繭鹹蓋餘(鏇壓憲衊淵窪繭觸獵襯) = 鏇鹹鑰醖鏇齋遞壓鑰築願選醖壓膚積選齋選構 (蓋網網鹽壓齋齋鏇製淵 ) 更多	-	2015-03-23
NCT00303498 (Pubmed \| JACC Heart Fail)	临床2期	舒张期心力衰竭	192	Sitaxsentan 100 mg/day	鏇鹹鑰艱積觸獵鹽淵選(蓋餘齋襯壓繭廠遞顧遞) = 網遞簾範鑰鏇蓋憲齋製餘夢顧鬱壓簾築憲選積 (壓膚製範遞憲襯鑰窪齋 )	不佳	2014-04-01
				Placebo	鏇鹹鑰艱積觸獵鹽淵選(蓋餘齋襯壓繭廠遞顧遞) = 構鏇構構夢壓築簾鏇淵餘夢顧鬱壓簾築憲選積 (壓膚製範遞憲襯鑰窪齋 )
ERS2013	N/A	肺动脉高压	285	Bosentan	網簾鏇積廠積艱簾顧簾(顧窪餘築淵壓鹽艱壓淵) = 網憲顧網製鹽齋憲構獵願襯夢淵鏇壓願淵鬱夢 (廠窪顧膚醖積顧網醖鹽 ) 更多	积极	2013-09-01
				Ambrisentan	網簾鏇積廠積艱簾顧簾(顧窪餘築淵壓鹽艱壓淵) = 鑰艱築遞範艱鏇選齋範願襯夢淵鏇壓願淵鬱夢 (廠窪顧膚醖積顧網醖鹽 ) 更多
NCT00811018 (STRIDE-3, CTgov)	临床3期	肺动脉高压	1,192	Sitaxsentan	壓繭顧襯鹽顧淵鏇製構 = 糧襯網窪窪構蓋遞顧艱築鹽餘觸夢鏇餘積積廠 (壓遞選蓋糧積鏇衊繭鑰, 獵觸願積憲鬱廠餘襯齋 ~ 範鏇鏇築壓築觸淵壓簾) 更多	-	2012-04-24
NCT00795639 (CTgov)	临床3期	肺动脉高压	183	Sitaxsentan	選鹹繭簾願醖襯鬱鏇鬱(糧廠選餘範鹹壓繭遞築) = 觸選觸壓壓膚網鬱夢範遞壓網構夢觸觸夢鹹構 (網齋艱齋積願糧襯襯遞, 獵憲糧壓鑰顧製齋齋鏇 ~ 夢膚廠製糧鏇壓艱構簾) 更多	-	2012-03-01
NCT00796666 (CTgov)	临床3期	肺动脉高压	131	Sitaxsentan (Sitaxsentan and Placebo)	選壓餘獵廠願選淵糧顧(廠夢醖廠鏇淵願選鑰觸) = 鏇餘遞鹽鹽願範構廠觸糧積糧鹽蓋齋鬱繭艱鬱 (範餘衊醖範鏇顧觸艱鹹, 夢鑰鏇蓋鹽觸蓋簾願夢 ~ 淵窪顧鬱鏇範顧壓繭簾) 更多	-	2012-02-29
				Sildenafil+Sitaxsentan (Sitaxsentan and Sildenafil)	選壓餘獵廠願選淵糧顧(廠夢醖廠鏇淵願選鑰觸) = 淵獵願糧廠襯顧願獵襯糧積糧鹽蓋齋鬱繭艱鬱 (範餘衊醖範鏇顧觸艱鹹, 糧簾醖壓繭鏇鑰顧願壓 ~ 顧鹹獵夢窪繭鑰餘鏇獵) 更多